Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,279
Stocks News & Analysis
stocks
Earnings margins to improve for mining specialist
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.20 | 8.50 | -0.09% |
| CAC 40 | 8,278.77 | 7.63 | -0.09% |
| DAX 40 | 26,046.40 | 43.08 | 0.17% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,831.09 | 0.43 | -0.00% |
| HKSE | 25,374.96 | 275.91 | -1.08% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 66,058.65 | 1,037.71 | 1.60% |
| NZX 50 Index | 13,920.81 | 53.37 | -0.38% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,013.10 | 10.30 | -0.11% |
| SSE Composite Index | 3,920.70 | 9.42 | -0.24% |